首页> 美国卫生研究院文献>BMC Anesthesiology >NT-proBNP in cardiopulmonary resuscitated patients treated with mild therapeutic hypothermia is not independently associated with mortality: a retrospective observational study
【2h】

NT-proBNP in cardiopulmonary resuscitated patients treated with mild therapeutic hypothermia is not independently associated with mortality: a retrospective observational study

机译:回顾性观察研究:经轻度治疗性低温治疗的心肺复苏患者中的NT-proBNP与死亡率无关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIn spite of the introduction of mild therapeutic hypothermia (MTH), mortality rates remain high in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA). To date, no accurate and independent biomarker to predict survival in these patients exists. B-type natriuretic peptide (BNP) was found to provide both prognostic and diagnostic value in various cardiovascular diseases, including survival to hospital discharge in patients with ROSC. However, the biologically inactive counterpart of BNP, NT-proBNP, was found to be a more stable and accurate analyte. The current retrospective observational study investigates the value of NT-proBNP to predict 28-day mortality in post-CA patients treated with MTH, as well as the dynamics of NT-proBNP during MTH.
机译:背景技术尽管引入了温和的治疗性低温(MTH),但心脏骤停(CA)后自发性循环(ROSC)恢复的患者的死亡率仍然很高。迄今为止,尚不存在准确且独立的生物标志物来预测这些患者的生存。发现B型利钠肽(BNP)在各种心血管疾病中均具有预后和诊断价值,包括ROSC患者的出院生存率。但是,发现BNP的无生物活性的对应物NT-proBNP是一种更稳定和准确的分析物。当前的回顾性观察研究调查了NT-proBNP预测MTH治疗的CA后患者28天死亡率的价值以及MTH期间NT-proBNP的动态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号